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Primary aldosteronism has been considered a rare disease in the past years, aﬀecting 1% of the hypertensive population.
Subsequently, growing evidence of its higher prevalence is present in literature, although the estimates of disease range from
5 up to 20%, as in type 2 diabetes and resistant hypertension. The main reasons for these variations are associated with the
selection of patients and diagnostic procedures. If we consider that hypertension is present in about 20% of the adult population,
primary aldosteronism can no longer be considered a rare disease. Patients with primary aldosteronism have a high incidence of
cardiovascular, cerebrovascular and kidney complications. The identiﬁcation of these patients has therefore a practical value on
therapy, and to control morbidities derived from vascular damage. The ability to identify the prevalence of a disease depends on
the number of subjects studied and the methods of investigation. Epidemiological studies are aﬀected by these two problems: there
is not consensus on patients who need to be investigated, although testing is recommended in subjects with resistant hypertension
and diabetes. The question of how to determine aldosterone and renin levels is open, particularly if pharmacological wash-out is
diﬃcult to perform because of inadequate blood pressure control.
1.Introduction
The history of primary aldosteronism (PA) is that of an
uncommon cause of hypertension until up to 15 years ago.
In 1954, Conn studied a 34-year-old female with high blood
pressure, severe hypokalemia, and mild hypernatremia,
discovering an averaged 22-fold higher mineralcorticoid
activity per day in comparison with normotensive controls:
this clinical condition reversed after the removal of a right
adrenal mass. Thereafter, Conn stated in his presidential
address “It is believed that these studies delineate a new clinical
syndrome which is designated as primary aldosteronism.”
Primary aldosteronism, as deﬁned by Conn in 1955 [1],
was widely thought to be present in approximately 1% of
hypertensive patients [2, 3]. Today primary aldosteronism
c a nb ed e ﬁ n e da sag r o u po fd i ﬀerent disorders (Table 1), “in
whichaldosteroneproductionisinappropriatelyhigh,relatively
autonomous from the renin-angiotensin system, and non sup-
pressible by sodium loading”[ 4]. Several studies suggest that
PA is the most common cause of secondary hypertension,
althoughtheprevalenceisvariablefrom5to20%,depending
on patient selection and methods of diagnosis. There are
changes in the perceived epidemiology of the disease because
as Gordon observed “normokalemic primary aldosteronism
has been known for 50 years, always there, but not recognized
because patients were not tested for it”[ 5]. Recent studies
highlight that only a minority of patients with PA presents
with hypokalemia and normokalemic hypertension is the
most common presentation of the disease, particularly in the
case of idiopathic hyperaldosteronism (IHA). Variability in
the prevalence of PA can be due to diﬀerences in aldosterone
to renin ratio (ARR) cutoﬀ values, defects in the use of
functional tests, or suboptimal sampling conditions such as
the maintenance of some medications or bias in the selection
of patients. Strong evidence supports the hypothesis that
aldosterone plays a pivotal role in hypertension, even if the
classicaldiagnosisofprimaryaldosteronismcannotbemade.
Finally, is the diagnosis of aldosteronism essential in the
strategies we need to adopt in treating high blood pressure
and related comorbidities?2 International Journal of Hypertension
Table 1: Subtypes of primary aldosteronism [6].
Aldosterone-producing adenoma (APA)—35% of cases
Bilateral idiopathic hyperplasia (IHA)—60% of cases
Primary unilateral adrenal hyperplasia—2% of cases
Pure aldosterone-producing adrenocortical carcinoma—<1% of cases
Familial hyperaldosteronism
Type I = glucocorticoid remediable aldosteronism—<1% of cases.
Type II = familial APA or IHA—<2% of cases.
Ectopic aldosterone-producing adenoma or carcinoma—<0.1% of cases
2.MaterialsandMethods
2.1. Data Sources and Searches. We conducted a search on
thePubMeddatabaseforepidemiologicalstudiesonprimary
aldosteronism using terms to identify clinical settings as fol-
lows: ([Primary Aldosteronism] AND [epidemiology] AND
[hospital setting] OR [general population] OR [essential
hypertension] OR [refractory hypertension] OR [diabetes]
OR [aldosterone antagonist] OR [angiotensin II receptor
antagonist]OR[angiotensinconvertingenzymeinhibitors]).
The search was limited to articles published up to February
2011. A subsequent search was performed for clinical trials
using terms for identiﬁcation as follows: ([aldosteronism]
AND [target organ damage] OR [heart] OR [kidney] OR
[endothelium] OR [mesangium]). Clinical trials with an
active treatment period of ≥4 weeks were included.
3. Aldosterone and Hypertension
Mineralcorticoid antagonists are extremely eﬃcient in the
treatment of hypertension [7]. Eplerenone is able to reduce
blood pressure in unselected patients with mild to moderate
hypertension [8], with an add-on eﬀect if patients are treated
with ACEi [9], and its eﬀect on uncontrolled hypertensive
patients on ACE-I or ARB was not predicted by the base-
line value of aldosterone/PRA (ARR) ratio [10]. Of note, al-
dosterone receptor antagonists need to be used with care,
because they can induce an increase of potassium especially
if renal function is impaired. In the case of renin angiotensin
aldosterone system (RAAS) inhibition monotherapy, min-
eralcorticoid antagonists increase the level of potassium
marginally but, in the case of dual RAAS inhibition, when
associated with ACEi/ARB, a higher incidence of serum po-
tassium >5.5mmol/L has been reported in up to 5.6% of
patients [11]. Amiloride blocks the epithelial-sodium chan-
nel (ENaC) as an indirect aldosterone antagonist, oppos-
ing the upregulating action of mineralocorticoids on this
transport and, consequently, reduces the sodium and ﬂuid
overload. The addition of amiloride in the therapy for resist-
ant hypertension can induce a signiﬁcant blood pressure
decrease in low-renin hypertensive patients [12]. Is it aldos-
teronism or inappropriately high levels of aldosterone?
A method for answering this question is another ques-
tion: are aldosterone levels able to predict future hyperten-
sion, supporting a causal role? The Framingham Oﬀspring
Study reported that serum aldosterone levels predicted the
development of hypertension in normotensive subjects [13]
and high ARR is predictive of the worsening of hypertension.
The study of Newton-Cheh and coworkers [14] analyzed the
3-year followup of 607 normotensive individuals participat-
ing in the Framingham study, revealing that 34.2% expe-
rienced BP progression and 16% developed hypertension.
Dividing patients into quartiles of ARR, the upper quartile
was associated with an 89% increased risk of blood pressure
progression and a 53% increased risk of hypertension.
They also observed that ARR was hereditary and a modest
correlation with chromosome 11p was reported. The eﬀect
of aldosterone is not associated exclusively with sodium
retention, but with a multitude of proﬁbrotic and proinﬂam-
matory eﬀects, and its blockade induces a 40% reduction of
urinary excretion of type IV collagen [15] and of glomerular
mesangial injury [16]. From these considerations, we pro-
ceed to the concept that aldosterone per se has a critical role
in a signiﬁcant number of patients with hypertension.
4. Epidemiology of PrimaryAldosteronism
If we consider the relationship between primary aldostero-
nism and hypertension, we are moving into the ﬁeld of
awareness that increased levels of aldosterone in relation to
normal range are an important cause of secondary hyper-
tension (Table 2). How frequent is primary aldosteronism?
The Harvey Lecture of Conn held in 1967 reports “While we
were theorizing about the possible existence of normokalemic
primary aldosteronism and before we have actually described
it, we had suggested on the basis of autopsy report and other
indirect evidence, that primary aldosteronism could actually
involve as many as 20 percent of people with “essential
hypertension.” Although our own work in this regard is far
from complete, it appears that the determined value will not
be as high as predicted. At present 10 percent appear to be more
realistic”[ 17].
Atthebeginningofthe1990s,Gordonetal.reportedthat
12% of 52 individuals enrolled in a hypertensive drug trial
were positive for primary aldosteronism. The diagnosis was
made after the determination of ARR and by using a sup-
pression test, namely, ﬂudrocortisone acetate administration
plus oral salt loading. Remarkably, none of the 6 patients
in this study presented hypokalemia. The study concluded
that “The incidence of primary aldosteronism is probably much
higher than the 1% currently quoted in texts, with earlier,
normokalemic forms accounting for the majority of cases”[ 18].International Journal of Hypertension 3
Table 2: Epidemiology study on primary aldosteronism.
Author Ref. Clinical setting Number of
Patients Type of study Diagnostic Criteria Conﬁrmatory
test for PA Prevalence
Conn 1967 [17] Hypothesis 10%
Fishman et al. 1969 [2] Hospital 90 EH Prospective Increased aldosterone or
suppressed PRA levels No <1%
Gordon et al. 1990 [18] Hospital 52 EH Prospective ARR Yes 12%
Gordon et al. 1994 [19] Hospital 199 EH Prospective ARR Yes 8.5–12%
Fardella et al. 2000 [20] Hospital 305 EH Prospective ARR > 25 Yes 9.5%
205 NT
Newton-Cheh et al. 2008 [14] General pract. 3326 EH Retrospective Aldosterone/plasma
renin > 26ng/L mU/L No 7.9–31.1%
Olivieri et al. 2004 [21] General pract. 412 EH Prospective Aldosterone/active renin
> 32pg/mL No 32.4%
Rossi et al. 2006 [22] Hospital 1125 EH Prospective ARR > 25 Yes 11.2%
Williams et al. 2006 [23] Hospital 347 EH Prospective ARR > 25 Yes 3.4%
Calhoun et al. 2002 [24] Hospital—RH 88 EH Prospective PRA < 1ng/mL/h Yes 20%
u.Aldosterone >
12pg/24h
Gallay 2001 [25] Hospital—RH 90 EH prospective ARR > 100 Yes 19%
Strauch et al. 2003 [26] Hospital—RH 402 EH prospective ARR > 100 Yes 19%
Di Murro et al. 2010 [27] Hospital—OSA 325 EH prospective ARR > 40 Yes 33.9%
Mukherjee et al. 2010 [28] Hospital—diabetes 100 EH prospective ARR > 550 Yes 13%
Aldosterone = pmol/L
Unpierrez et al. 2007 [29] Hospital—diabetes 100 EH prospective ARR > 30 Yes 14%
RH:resistanthypertension;OSA:obstructiveapneasyndrome;EH:essentialhypertension;NT:normotensivepatients;ARR:aldosterone/plasmareninactivity.
One year later, in 1994, the same authors reported in 199
patients referred to the Hypertension Clinic of Brisbane a
prevalence of 8.5% up to probably 12% [19]. The character-
isticsofthesepatientswerehypertensionandnormokalemia;
that is, the diagnosis was made in patients without a clinical
suspicion of primary aldosteronism. The cutoﬀ value of
serum aldosterone/plasma renin activity ratio (SA/PRA =
ng/dL/ng/mL/h) could be a bias in the diagnosis of PA. Some
years later, Fardella et al. [20]u s e dt w oc u t o ﬀsf o rS A / P R A
ratio: a ratio greaterthan 25 wasdeﬁnedas ahigh level,while
a ratio greater than 50 corresponded to a very high level.
Diagnosis of probable PA was made for an SA/PRA ratio >25
without other criteria, while diagnosis of highly probable PA
was established for a ratio higher than 50. To conﬁrm the
diagnosis, the ﬂudrocortisone test was performed while the
diﬀerentiation test for glucocorticoid-remediable aldostero-
nism (GRA) was made using the dexamethasone test, with
determination of 18-hydroxicortisol and genetic detection
of the chimeric gene responsible for GRA (aminoacid
substitution S288G and V320A in the CYP11B1 gene). The
study was based on 305 unselected essential hypertensive
(EH) patients and 205 normotensive controls. Hypertensive
patients showed higher levels of SA and SA/PRA ratio than
controls. In EH patients, the diagnosis of primary aldos-
teronism was made for 29 patients, corresponding to 9.5%;
13 patients had very high SA/PRA ratio and ﬂudrocortisone
testing conﬁrmed the diagnosis in all of them; the other
16 patients were deﬁned at the beginning as probable PA.
The diagnosis of probable PA was made on a total of 31
patients corresponding to 10.2%. Probable PA was deﬁned as
normal aldosterone levels but SA/PRA ratio >25 or elevated
aldosteronelevelsandnormalSA/PRAratio.Fludrocortisone
testing conﬁrmed the diagnosis of PA in 16 patients. 34.5%
of patients with PA had a positive dexamethasone test,
but elevated 18-hydroxycortisol levels were present in only
2 subjects. In all of the 29 patients with PA, plasma
potassium was normal, demonstrating that hypokalemia can
no longer be considered as a requisite for the diagnosis of
primary aldosteronism. In normotensive controls, PA was
diagnosedin3cases(1.46%).Insummary,theFardellastudy
d e m o n s t r a t e dap r e v a l e n c eo f9 . 5 %o fP Ai nu n s e l e c t e dE H
and reported the limited utility of dexamethasone test in
discriminating GRA. Their conclusions pointed to the need
for a routine determination of SA and PRA in all essential
hypertensive patients and that serial determination of 18-
hydroxycortisol levels should be performed in positive cases.
This study was performed in a university setting; there-
fore, the diﬀerence with the general population can be con-
siderable.
More recently, the Framingham Oﬀspring Study [14]
reported aldosterone/plasma-renin concentration ratio ex-
ceeding 26ng/L per mU/L in 7.9% and 23.1% of untreated
hypertensive men and woman, respectively, and in 24.6%
and 31.1% of men and woman on β-blockers. In this
study, ARR was measured only once, sodium intake was
not standardized, and suppression tests were not executed;4 International Journal of Hypertension
therefore, a limit to this epidemiological observation was
present, although it does reﬂect a large community-based
investigation.
The Bussolengo Study [21] was carried out in a primary
care setting. A sampling of 1462 patients referred by general
practitioners, aged 35–74 years, were randomly selected and
studied. 412 patients were identiﬁed as hypertensive (28.2%)
and 287 gave their consent to blood analysis (69.6%). Direct
active renin and aldosterone were measured in these hyper-
tensive subjects. The aldosterone/active renin ratio (AARR)
was considered positive for values >32pg/mL, which corre-
sponded to ARR > 50ng/dL/ng/mL/h. This last cutoﬀ has a
relatively high sensitivity and speciﬁcity for the diagnosis of
aldosteronism [30]. About one of three patients (32.4%) had
an elevated AARR. The study cannot demonstrate clearly the
prevalence of hyperaldosteronism in a general hypertensive
population, because conﬁrmatory tests were not performed
and a prudent practice could be the repetition of AARR, but
the suggestion that a large population can reap beneﬁts from
antialdosterone drug therapy does arise.
A large study was carried out by Rossi et al. [22]o n
1125 hypertensive patients referred to 14 specialized hyper-
tension clinics throughout Italy. Plasma renin activity and
plasma aldosterone were measured at baseline and again
60 minutes after administration of 50mg of captopril. The
subjects then had a saline suppression test, and 126 patients
were identiﬁed as presumed PA, corresponding to 11.2%.
Taking into account patients with primary aldosteronism,
an aldosterone producing adenoma (APA) was found in 54
of them, 43% of cases, with the remainder considered to
have idiopathic hyperaldosteronism (IHA). Diﬀerent results
on PA prevalence were reported by Williams and coworkers
[23]. They observed a low prevalence of primary aldos-
teronism in a group of 347 hypertensive volunteers: they
analyzed ARR, plasma, and urine aldosterone, on diﬀerent
salt diet regimens. Only 3.4% of patients were diagnosed
with PA. The large diﬀerence in prevalence with the other
studies brings to light the question of patient selection,
because subjects with plasma potassium <3.5mEq/L were
excluded, as well as patients with diastolic BP > 110mmHg
while on two or more medications. The analysis of these
two last studies follows up on the question suggested by
Kaplan [31]: is there really an unrecognized epidemic of
aldosteronism?TheRossistudycouldbelimitedbyanumber
of problems, as Kaplan observes, one of them being related
to the fact that only one set of ARR was performed; on
the other hand, the Williams study could have the bias that
patients were excluded from the study on the basis of low
plasma potassium and resistant hypertension. The bias of
patient selection in the Williams study could be reasonably
evoked, because it is clearly demonstrated that primary
aldosteronism is more prevalent in essential hypertensives
classiﬁed as stage 2 and 3 JNC VI [32].
Three years after Kaplan’s observations, a recent study by
Rossi [33] demonstrated that ARR has a good reproducibil-
ity, contrary to the previously claimed poor reproducibility
[34].
As Gordon observes in answering the question “primary
aldosteronism—actual epidemics or false alarm?,” “Epi-
demics is an inappropriate term”, but, at the same time, PA is
not a “false alarm,” because “false alarm suggests that we can
all relax again and get back to our real work”[ 5]. In summary,
the question of primary aldosteronism prevalence remains
open. It seems reasonable to assert that PA can be present
in up to 15–20% of hypertensive patients, depending on




Are there subgroups of essential hypertensive patients that
more frequently can be diagnosed as aﬀected by primary
aldosteronism? The study of Mosso and coworkers [32]
reportsthattheprevalenceofPAconﬁrmedwithsuppression
test was diagnosed in 6.1% of 609 patients treated in primary
care centers. Dividing all patients into groups based on
blood pressure values and relating them to a control group,
primary aldosteronism prevalence was 1.55% in normal
subjects, 1.99% in Stage 1 hypertension JCN IV (SBP 140 to
159mmHg, DBP 90 to 99mmHg), 8.02% in Stage 2 (SBP
160 to 179mmHg, DBP 100 to 109mmHg), and 13.2% in
Stage3(SBP>180mmHg,DBP>110mmHg)hypertension.
Those having PA were younger and took a larger number of
drugs for BP control. Of interest is the fact that only 1 out
of 29 PA patients had mild hypokalemia, and the researchers
explainedthelowfrequencyofreducedserumpotassiumlev-
els as the result of screening and referral of these patients to
secondary centers. Estimating the prevalence of hypokalemic
PA close to 1.5%, they reported a total prevalence of 7.5%.
But the point is that 13.2% of patients at hypertension
S t a g e3J N CI Vh a dP A .C a l h o u na n dc o w o r k e r sh a v e
studied 88 patients referred to a university clinic for resistant
hypertension (hypertensive subjects requiring 3 or more
diﬀerent antihypertensive medications at pharmacologically
eﬀective doses) [24]. 20% of them had primary aldostero-
nism on thebasis of suppressedplasma renin activity (PRA<
1.0ng/mL/h) and high urinary aldosterone (>12pg/24h),
in the presence of a high-sodium diet (>200mEq/24h).
They were treated with spironolactone with a consistent and
signiﬁcant reduction of BP (−26 ± 15.7/−12 ± 12.6mmHg).
Gallay in Seattle reported a prevalence of PA in 17% of
patients with resistant hypertension [25]; similarly, Strauch
et al. in Europe [26] and Eide and colleagues have reported
primary aldosteronism in 23% of patients with RH [35].
Although cause-and-eﬀect has not been conﬁrmed, it
appears that the increased occurrence of primary aldostero-
nismmaybelinkedtotheincreasingincidenceofsleepapnea
syndrome and obesity.
Di Murro and colleagues [27] reported a prevalence of
33.9% of primary aldosteronism in hypertensive patients
with sleep apnea syndrome. Pratt-Ubunama and coworkers
reported 85% prevalence of obstructive apnea syndrome
(OSA) in resistant hypertensive patients, and serum aldos-
terone levels were higher than in patients with OSA without
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visceral obesity frequently have elevated plasma aldosterone
levels, but the mechanism is unknown. An increased aldos-
terone secretion could be secondary to a decreased secretion
ofatrialnatriureticpeptide,whichseemstobereducedinthe
case of obesity [37].
6.PrimaryAldosteronismandDiabetes
Type 2 diabetic patients are frequently aﬀected by hyperten-
sion, and approximately 50–75% fail to achieve satisfactory
blood pressure control [38]. This is one cause of the
high incidence of cardiovascular complications, such as
heart failure, stroke, and kidney disease. A close relation-
ship between aldosterone and insulin resistance has been
demonstrated: hyperinsulinemia stimulates the production
ofaldosterone,andanexcessofmineralocorticoidscancause
the resistant hypertension observed in diabetic patients.
Mukherjee and coworkers [28]h a v es t u d i e dp r o s p e c t i v e l y
100 Asian type 2 diabetic patients with uncontrolled hyper-
tension and have analyzed ARR ratio. Those with a ratio
>550pmol/L/ng/mL/h underwent a conﬁrmatory saline test,
and, in the case of high aldosterone levels, imaging investi-
gations and adrenal vein sampling were performed. Thirteen
patients (13%) were diagnosed with primary aldosteronism;
their blood pressure was signiﬁcantly higher, 46% had
plasma potassium levels lower than 3.5mmol/L, and 62%
of them had a surgically correctable form of PA. The
limitation of this study was linked to the diﬃculties in safely
withdrawing antihypertensive medications; therefore, a false
negativeratiocouldbepresentandthesalinetesttoindentify
these was not performed on all patients. Consequently, a
higher prevalence of PA may have been present in this
population. Another report by Umpierrez and colleagues
[29] screened 100 patients with type 2 diabetes and resistant
hypertension, measuring ARR and performing conﬁrmatory
salt load tests in subjects with a ratio >30ng/dL/ng/mL/h.
They observed an increased ARR in 34% of patients, and
14% of them had primary aldosteronism. These results
have a potentially great impact, because, for each 10
mmHg decrease of systolic BP, there is a 13% reduction of
microvascular complications, a 12% decreased risk of fatal
andnonfatalmyocardialinfarction,anda17%decreasedrisk
of death [39]. From these data arises the recommendation to
investigate primary aldosteronism in all patients with type 2
diabetesandresistanthypertension,becauseitsidentiﬁcation
couldhaveatremendousimpactonachievingBPcontroland




The detection of primary aldosteronism is central in the
study of essential hypertension for at least two reasons: the
ﬁrst is linked to therapeutic strategies, such as the indication
forsurgicalproceduresinthepresenceofadenomaortheuse
of mineralcorticoid antagonists. The second is the observa-
tion that cardiovascular and cerebrovascular complications
may be more common in the case of PA.
Milliez and colleagues reported that the stroke rate was
12.9% in PA subjects, compared to 3.4% observed in a
control group matched for age, gender, and blood pres-
sure levels [40]. They also observed a higher incidence of
myocardial infarction and atrial ﬁbrillation in PA subjects.
Catena and coworkers [41] have studied 54 patients with
PA and compared left ventricular mass (LVM) and function
before and after treatment with a group of 274 patients
with essential hypertension. At baseline, the groups were
similar in clinical characteristics and blood pressure control,
but signiﬁcantly higher LVMi were observed in patients
with aldosteronism. Decreased diastolic function was also
reported. After one year of treatment, signiﬁcant reductions
of blood pressure and LVMi were present, and after an aver-
age period of 6.4 years of followup, LV mass further de-
creased, but not BP. The percentage reduction of LVMi was
higher in patients with idiopathic hyperaldosteronism who
underwent medical therapy than in the adenoma-producing
aldosterone group, who were surgically treated. The cardiac
changes observed in the period between one year and the
end of study lead us to suppose that factors other than vol-
ume stress, which can result from the renal eﬀects of aldos-
terone, or blood pressure are responsible for these changes.
The activation of cardiac receptors might play a role in left
ventriclehypertrophyandremodeling.Itisknownthatinter-
actions of aldosterone with angiotensin, endothelin, or brad-
ykinin activate inﬂammatory cells and ﬁbroblast prolifera-
tion, leading to collagen synthesis. Independently of blood
pressure, aldosterone exerts detrimental eﬀects on small
vessels, such as pronounced ﬁbrosis, and on heart geometry
andfunction.Theresultofanincreasedﬁbrosis[42]explains
the failure in diastolic function.
Clinical outcome in terms of myocardial infarction,
stroke, revascularization procedures, and sustained arrhyth-
mias was analyzed by the same authors after 7.4 years [43].
Before the beginning of treatment, at basal time, a history
of cardiovascular events was present in 34% of patients with
PA, signiﬁcantly higher than the 11% registered in essential
hypertension group. After treatment, at the end of followup,
endpoint was reached in 19% of patients with PA, and 18%
of essential hypertensives, demonstrating the importance of
correction of hyperaldosteronism.
Of interest is the study of the German Conn’s Registry
[44]: a population of 553 patients with PA was investigated,
of which 56.1% had hypokalemia. They diﬀered from nor-
mokalemic patients because of higher BP levels, but ther-
apeutic strategies were not diﬀerent between the groups.
Aldosterone was signiﬁcantly higher in patients with low
potassium levels, and a correlation with the prevalence of
vascular comorbidities was observed. The prevalence rate for
cardiovascularevents,suchasanginaorcardiacinsuﬃciency,
was higher in the hypokalemic group.
Al a r g e rw o r k[ 45], the Ludwigshafen Risk and Cardio-
vascular Health (LURIC) study, analyzes comorbidity and
survival in a group of 3153 patients with ischemic heart dis-
ease who underwent coronary angiography. The study eval-
uated ARR, and 3.1% of patients had a ratio >50. After the
division in quartiles on the basis of plasma aldosterone con-
centration, hazard ratio (HR) of all-cause death was higher6 International Journal of Hypertension
for quartiles with higher ARR. In fully adjusted analysis,
patients of the fourth quartile had an increased risk of fatal
stroke (HR = 7.02). Again, this study addresses the question
of primary aldosteronism or elevated levels of aldosterone
andpointsouttheneedtoconsidermineralcorticoidantago-
nists in medical treatment strategies. Some populations ben-
eﬁt from aldosterone antagonist therapy: this is true not only
for hypertensive patients with primary aldosteronism, but
also in patients with heart failure and chronic kidney disease.
However, patients in these last two groups must be carefully
observed for the development of potentially fatal hyper-
kalemia. The RALES trial demonstrates that, when added to
ACEi, aldosterone receptor antagonists decreased mortality
by 30% in NYHA class III and IV over a period of 24
months [46]. The addition of eplerenone or spironolactone
in diabetic patients with proteinuria to ACEi or angiotensin
receptor antagonists seems to reduce protein excretion,
whichisacausativefactorofkidneydiseaseprogression[47].
8. Summary
The prevalence of primary aldosteronism cannot be precisely
determined at this time. It is signiﬁcantly more common
than previously thought, representing probably the most
common cause of secondary hypertension. Changes in
the perceived epidemiology of PA are the consequence
of increased investigations in normokalemic hypertensive
patients, and this represents an evolution from the historical
deﬁnition of the disease. Using plasma aldosterone to plasma
reninactivityratiofollowedbyaldosteronesuppressiontests,
the prevalence in hypertensive patients can be estimated in
the range of 5–12%. A higher prevalence up to 15–20% is
highly probable in selected patients, such as those with type
2 diabetes and refractory high blood pressure or sleep apnea
syndrome. In these populations, the study of aldosterone
shouldbeconsideredasroutineintheﬂowchartofdiagnostic
procedures and hypokalemia should not be a determinant in
the screening process. The identiﬁcation of primary aldos-
teronism has a signiﬁcant prognostic value, because these
patients are subject to increased cardiovascular risk, which
can be reduced by proper medical or surgical treatment,
depending on the cause, be it idiopathic or due to adenoma.
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